medigraphic.com
ISSN 2007-2783 (Impreso)
Órgano Oficial del Instituto Científico Pfizer

2013, Número 3

<< Anterior Siguiente >>

Residente 2013; 8 (3)


Las adipocinas como mediadoras en la inflamación y el sistema inmune

Nava-Santana CA, Guerra-Soto AJ, Mendoza-Vázquez G, Flores-Chávez A, Nava A

Idioma: Español
Referencias bibliográficas: 53
Paginas: 97-105
Archivo PDF: 400.06 Kb.


RESUMEN

La obesidad es la protagonista de una epidemia a nivel mundial que cobra una gran cantidad de vidas a causa de sus complicaciones y enfermedades asociadas, como las patologías cardiovasculares, que son las mayores causas de mortalidad en el mundo. Hoy en día la obesidad es considerada un estado proinflamatorio. Las adipocinas incluyen una gran variedad de péptidos proinflamatorios que contribuyen notablemente a un estado de inflamación subclínica y promueven una serie de alteraciones metabólicas que comprenden complicaciones cardiovasculares y enfermedades inflamatorias autoinmunes. El presente artículo pretende realizar una actualización del tejido adiposo como órgano secretor de múltiples intermediarios metabólicos y describir los hallazgos más recientes relativos a la implicación de las adipocinas en la respuesta inflamatoria e inmune.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Zimmermann-Belsing T, Feldt-Rasmussen U. Obesity: the new worldwide epidemic threat to general health and our complete lack of effective treatment. Endocrinology. 2004; 145 (4): 1501-1502.

  2. Prins JB. Adipose tissue as an endocrine organ. Best Pract Res Clin Endocrinol Metab. 2002; 16 (4): 639-651.

  3. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab. 2003; 14 (3): 137-45.

  4. Spiegelman BM, Enerback S. The adipocyte: a multifunctional cell. Cell Metab. 2006; 4 (6): 425-427.

  5. Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes. 2006; 55: 1537-1545.

  6. Fruhbeck G, Gomez-Ambrosi J, Muruzabal FJ, Burrell MA. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab. 2001; 280 (6): E827-E847.

  7. Moreno-Aliaga MJ, Campión J, Milagro FI, Berjón A, Martínez JA. Adiposity and proinflammatory state: the chicken or the egg. Adipocytes. 2005; 1: 1-16.

  8. Sjoholm A, Nystrom T. Inflammation and the etiology of type 2 diabetes. Diabetes Metab Res Rev. 2006; 22 (1): 4-10.

  9. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993; 259: 87-91.

  10. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006; 6: 772-783.

  11. Gómez R, Conde J, Gómez-Reino JJ, Lago F, Gualillo O. Adipocytokines: emerging mediators of the immune response and inflammation. Reumatol Clin. 2009; (Suppl. 1): 6-12.

  12. Sánchez JC, López D, Pinzón A, Sepúlveda JC. Adipokines and metabolic syndrome: multiple aspects of a complex pathophysiological process. Revista Colombiana de Cardiología. 2010; 17 (4): 167-176.

  13. Gautron L, Elmquist JK. Sixteen years and counting: an update on leptin in energy balance. J Clin Invest. 2011; 121 (6): 2087.

  14. Parul Singla, Animesh Bardoloi, Anuj A Parkash. Metabolic effects of obesity: a review. World J Diabetes. 2010; 1 (3): 76-88.

  15. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994; 372 (6505): 425.

  16. Nawrot-Porabka K, Jaworek J, Leja-Szpak A, Palonek M, Szklarczyk J, Konturek SJ et al. Leptin is able to stimulate pancreatic enzyme secretion via activation of duodeno-pancreatic reflex and CCK release. J Physiol Pharmacol. 2004; 55 (Suppl. 2): 47-57.

  17. Botella C, Barbancho LL, González V, Varela D. Leptina: implicaciones fisiológicas y clínicas. An Med Interna. 2001; 18 (3): 152-160.

  18. Toussirot E, Gaugler B, Bouhaddi M, Nguyen N, Saas P, Dumoulin G. Elevated adiponectin serum levels in women with systemic autoimmune diseases. 2010; 2010: [6 p.]. pii: 938408. doi:10.1155/2010/938408.

  19. Coleman DL. Effects of parabiosis of obese with diabetes and normal mice. Diabetología. 1973; 9 (4): 294.

  20. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996; 334 (5): 292.

  21. Sinha MK et al. Nocturnal rise of leptin in lean, obese and non-insulin dependent diabetes mellitus subjects. J Clin Invest. 1996; 97: 1344-1347.

  22. San Miguel A, Calvo B, Alonso N, Iglesias R, Mazón M. Leptina: implicaciones fisiológicas y clínicas. Asociación Española de Farmacéuticos Analistas. 2005; 3: 28010.

  23. Tesauro M, Mascali A, Franzese O, Cipriani S, Cardillo C, Di Daniele N. Chronic kidney disease, obesity, and hypertension: the role of leptin and adiponectin. Int J Hyperten. 2012; 2012: [7 p.]. pii: 943605. doi:10.1155/2012/943605.

  24. Morton GJ. Hypothalamic leptin regulation of energy homeostasis and glucose metabolism. J Physiol. 2007; 583 (Pt 2): 437-443.

  25. Procaccini C, Lourenco EV, Matarese G, La Cava A. Leptin signaling: a key pathway in immune responses. Curr Signal Transduct Ther. 2009; 4 (1): 22-30.

  26. Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest. 2002; 110 (8): 1093.

  27. McMahon M, Skaggs BJ, Sahakian L, Grossman J, Fitzgerald J, Ragavendra N et al. High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidisedlipids. Ann Rheum Dis. 2011; 70: 1619-1624.

  28. Scotece M, Conde J, Gómez R, López V, Lago F, Gómez-Reino M. Beyond fat mass: exploring the role of adipokines in rheumatic diseases. Scientific World Journal. 2011; 11: 1932-1947.

  29. Maeda N, Takahashi M, Funahashi T et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001; 50 (9): pp. 2094-2099.

  30. Robinson K, Prins J, Venkatesh B. Clinical review: adiponectin biology and its role in inflammation and critical illness. Crit Care. 2011; 15: 221.

  31. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003; 423: 762-769.

  32. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007; 13: 332-339.

  33. Domínguez C. Adiponectina: el tejido adiposo más allá de la reserva inerte de energía. Revista de Endocrinología y Nutrición. 2007; 15 (3): 149-155.

  34. Gómez R, Conde J, Gómez JJ. Las adipocinas: mediadores emergentes de la respuesta inmune y de la inflamación. J Reuma. 2008; 5: 6-12.

  35. Rovin BH, Song H, Hebert LA et al. Plasma, urine, and renal expression of adiponectin in human systemic lupus erythematosus. Kidney International. 2005; 68 (4): 1825-1833.

  36. Sánchez-Muñoz F, García-Macedo R, Alarcón-Aguilar F, Cruz M. Adipocinas, tejido adiposo y su relación con células del sistema inmune. Gac Méd Méx. 2005; 141 (6): 505-512.

  37. Nogueiras R, González RC, Mendieta H, Lage R, Diéguez C. Resistina: una nueva hormona expresada en el tejido adiposo. Revista Esp Obes. 2005; 3 (4): 194-211.

  38. Santana PS. Las adipocitoquinas en la génesis y evolución del síndrome metabólico. Rev Cubana Aliment Nutr. 2010; 20 (2): 304-317.

  39. Zulet MA, Puchau B, Navarro C, Martí A, Martínez JA. Biomarcadores del estado inflamatorio: nexo de unión con la obesidad y complicaciones asociadas. Nutr Hosp. 2007; 22 (5): 511-527. ISSN 0212-1611.

  40. Mohapatra J, Sharma M, Acharya A, Pandya G, Chatterjee A, Balaraman R et al. Retinol-binding protein 4: a possible role in cardiovascular complications. Br J Pharmacol. 2011; 164 (8): 1939-1948.

  41. Kotnik P, Fischer-Posovszky P, Wabitsch M. RBP-4: a controversial adipokine. Eur J Endocrinol. 2011; 165 (5): 703-711.

  42. Keicho N, Matsushita I, Tanaka T, Shimbo T, Hang NT, Sakurada S et al. Circulating levels of adiponectin, leptin, fetuin-a and retinol-binding protein in patients with tuberculosis: markers of metabolism and inflammation. PLoS One. 2012; 7 (6): e38703.

  43. Koch A, Weiskirchen R, Sanson E, Zimmermann HW, Voigt S, Dückers H et al. Circulating retinol-binding protein 4 in critically ill patients before specific treatment: prognostic impact and correlation with organ function, metabolism and inflammation. Crit Care. 2010; 14 (5): R179.

  44. Bergmann K, Sypniewska G. Diabetes as a complication of adipose tissue dysfunction. Is there a role for potential new biomarkers? Clin Chem Lab Med. 2013; 51 (1): 177-185.

  45. Barazzoni R, Zanetti M, Semolic A, Pirulli A, Cattin MR, Biolo G et al. High plasma RBP-4 is associated with systemic inflammation independently of low RBP-4 adipose expression and is normalized by transplantation in non-obese, non-diabetic patients with chronic kidney disease. Clin Endocrinol. 2011; 75: 56–63. doi: 10.1111/j.1365-2265.2011.03990.x

  46. Farjo KM, Farjo RA, Halsey S, Moiseyev G, Ma JX. Retinol-binding protein 4 induces inflammation in human endothelial cells by an NADPH oxidase-and nuclear factor kappa B-dependent and retinol-independent mechanism. Mol Cell Biol. 2012; 32 (24): 5103-5115.

  47. Iglesias P, Selgas R, Romero S, Díez JJ. Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21. Eur J Endocrinol. 2012; 167 (3): 301-309.

  48. Kotulák T, Drápalová J, Kopecký P, Lacinová Z, Kramář P, Říha H et al. Increased circulating and epicardial adipose tissue mRNA expression of fibroblast growth factor-21 after cardiac surgery: possible role in postoperative inflammatory response and insulin resistance. Physiol Res. 2011; 60 (5): 757-767.

  49. Xu A, Vanhoutte PM. Adiponectin and adipocyte fatty acid binding protein in the pathogenesis of cardiovascular disease. Am J Physiol Heart Circ Physiol. 2012; 15; 302 (6): H1231-H1240.

  50. Hui X, Li H, Zhou Z, Lam KS, Xiao Y, Wu D et al. Adipocyte fatty acid-binding protein modulates inflammatory responses in macrophages through a positive feedback loop involving c-Jun NH2-terminal kinases and activator protein-1. J Biol Chem. 2010; 285 (14): 10273-10280.

  51. Dunmore SJ, Brown JE. The role of adipokines in β-cell failure of type 2 diabetes. J Endocrinol. 2013; 216 (1): T37-T45.

  52. Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci. 2009; 54 (9): 1847-1856.

  53. Xu S, Tsao PS, Yue P. Apelin and insulin resistance: another arrow for the quiver? J Diabetes. 2011; 3 (3): 225-231.




2020     |     www.medigraphic.com